Grufity logo
Grufity logo
VAXX

VAXX - Vaxxinity, Inc. Stock Price, Fair Value and News

$0.02+0.02 (+Infinity%)
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

VAXX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VAXX Price Action

VAXX RSI Chart

VAXX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VAXX Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0

EV/EBITDA

0.09

Price/Free Cashflow

0

VAXX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

VAXX Fundamentals

VAXX Revenue

VAXX Earnings

VAXX Profitability

Free Cashflow Yield

0%

VAXX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2022----
2021434.3K311.5K188.8K66.0K
2020---557.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Vaxxinity, Inc.

VAXX
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.
 CEO
 WEBSITEvaxxinity.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES87

Vaxxinity, Inc. Frequently Asked Questions

VAXX is the stock ticker symbol of Vaxxinity, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Vaxxinity, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, VAXX's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VAXX PE ratio will change depending on the future growth rate expectations of investors.